Mainz, Germany

Jens Daufenbach

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 7.8

ph-index = 1


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Jens Daufenbach

Introduction

Jens Daufenbach is a notable inventor based in Mainz, Germany. He has made significant contributions to the field of therapeutic proteins, particularly in the development of recombinant coagulation factors. With a total of two patents to his name, Daufenbach's work has the potential to greatly impact the treatment of patients with Hemophilia A.

Latest Patents

Daufenbach's latest patents include a de-immunized factor VIII molecule and pharmaceutical compositions comprising the same. This invention focuses on reducing the immunogenicity of recombinant Factor VIII (FVIII) proteins while retaining their coagulant activity. It also provides nucleic acids encoding the de-immunized protein, cell lines, and methods for recombinant preparation. This innovation is particularly beneficial for patients with Hemophilia A, especially those who have not previously been treated with FVIII products. Additionally, it offers a safe alternative for previously treated patients and those who have developed an immune response to FVIII. Another patent involves a process for preparing a powder that includes human coagulation factor proteins and a lactic acid polymer, which is essential for effective treatment.

Career Highlights

Throughout his career, Jens Daufenbach has worked with prominent companies such as Biotest AG and Evonik Röhm GmbH. His experience in these organizations has contributed to his expertise in the field of therapeutic proteins and coagulation factors.

Collaborations

Daufenbach has collaborated with notable colleagues, including Karina Winterling and Steffen Kistner. These partnerships have likely enhanced his research and development efforts in the field.

Conclusion

Jens Daufenbach's innovative work in the development of therapeutic proteins and coagulation factors showcases his commitment to improving patient care. His patents reflect significant advancements in the treatment of Hemophilia A, highlighting the importance of innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…